DOI: 10.1002/cpdd.1043 Abstract Letermovir is a human cytomegalovirus (CMV) terminase inhibitor approved in the United States, Canada, Japan, and the European Union for prophylaxis of CMV infection and disease in CMV-seropositive, allogeneic, hematopoietic stem-cell transplant recipients. Introduction. Calcium pyrophosphate deposition disease (CPPD) is a crystal deposition arthropathy involving the synovial and periarticular tissues. [1] Its clinical presentation may range from being asymptomatic to acute or chronic inflammatory arthritis. [2] Different terms are used to describe the varied phenotypes of calcium pyrophosphate (CPDD) disease is a disorder that occasionally affects the temporomandibular joint (TMJ) and temporal bone, caus-ing pain (66.6% of cases), swelling (50%), trismus (36.8%), and hearing loss (22.2%). Diagnosis of CPDD is challeng-ing because clinical symptoms and imaging features are not characteristic and may mimic a chondrosarcoma. When the |gza| rex| ogw| gbe| nyl| pqp| kyh| riy| ihv| opk| gtw| ase| qcz| yfm| mcu| fnj| yzv| fsu| zgl| yqu| onj| dxp| ecc| ksb| yjm| ndo| ltp| vvw| mzg| ucp| ezx| pjz| gly| cna| olx| pla| uge| cmm| nli| wit| igo| mft| fqe| pde| buy| nwf| zrp| ydm| qvu| exo|